文献速递浆细胞疾病

达雷妥尤单抗-来那度胺-地塞米松应答适应性挽救治疗适合移植但一线硼替佐米诱导失败的新诊断多发性骨髓瘤患者-ALLG MM21

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21.
PubMed 文献 · Br J Haematol · 2024-06-08

在澳大利亚,超过90%适合移植的新诊断多发性骨髓瘤患者接受硼替佐米为基础诱导治疗。该研究评估对硼替佐米诱导应答不佳或难治患者早期转换为达雷妥尤单抗-来那度胺-地塞米松(DRd)挽救、大剂量美法仑自体干细胞移植、DRd巩固及来那度胺维持的应答适应策略;4周期DRd挽救后总缓解率72%(95%可信区间57.9-82.4),达到预设双贝叶斯概念验证标准;12周期DRd巩固后意向治疗人群Euro-flow可测量残留病阴性率46%、可评估人群79%;24个月随访时中位无进展生存期和总生存期均未达到;DRd挽救耐受良好,3级和4级事件分别报告24%和8%。

要点

  • 4周期DRd挽救后总缓解率72%(95%可信区间57.9-82.4),达到预设双贝叶斯概念验证标准。
  • 12周期DRd巩固后Euro-flow可测量残留病阴性率意向治疗人群46%、可评估人群79%。
  • 24个月随访时中位无进展生存期和总生存期均未达到;DRd挽救3级和4级事件分别24%和8%。

核心结论

  • 应答适应性DRd联合自体干细胞移植在该功能高危组中达到高可测量残留病阴性率和持久疾病控制。

研究设计与样本

  • 研究评估对硼替佐米为基础诱导治疗应答不佳或难治的新诊断适合移植多发性骨髓瘤患者,早期转换为DRd挽救、大剂量美法仑自体干细胞移植、DRd巩固及来那度胺维持的强化序贯治疗策略。
  • 在澳大利亚,硼替佐米为基础诱导用于超过90%的新诊断适合移植多发性骨髓瘤患者;硼替佐米-环磷酰胺-地塞米松或硼替佐米-来那度胺-地塞米松4周期可通过药品福利计划在自体干细胞移植前使用。

主要发现

  • 4周期DRd挽救后总缓解率为72%(95%可信区间57.9-82.4),达到预设双贝叶斯概念验证标准。
  • 12周期DRd巩固后Euro-flow可测量残留病阴性率在意向治疗人群为46%、在可评估人群为79%。
  • 24个月随访时中位无进展生存期和总生存期均未达到。
  • DRd挽救耐受良好,3级和4级事件分别报告24%和8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Australia, bortezomib-based induction (V-IND) is used in >90% of newly diagnosed transplant-eligible multiple myeloma (MM) patients. Four cycles of V-IND with bortezomib-cyclophosphamide-dexamethasone or bortezomib-lenalidomide-dexamethasone are available via the Pharmaceutical Benefits Scheme prior to autologous stem cell transplantation (ASCT). Patients who demonstrate suboptimal response or who are refractory to V-IND demonstrate inferior survival, representing a subgroup of MM where an unmet need persists. We evaluated an early, response-adapted approach in these patients by switching to an intensive sequential therapeutic strategy incorporating daratumumab-lenalidomide-dexamethasone-based (DRd) salvage, high-dose melphalan ASCT followed by DRd consolidation and R maintenance. The overall response rate following four cycles of DRd salvage was 72% (95% credible interval: 57.9-82.4); prespecified, dual, Bayesian proof-of-concept criteria were met. Euro-flow minimal residual disease (MRD) negativity was 46% in the intention-to-treat population and 79% in the evaluable population following 12 cycles of DRd consolidation. At the 24-month follow-up, median progression-free survival and overall survival were not reached. DRd salvage was well tolerated with grade 3 and 4 events reported in 24% and 8% respectively. Response-adapted DRd combined with ASCT achieves high rates of MRD negativity and durable disease control in this functional high-risk group.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lim S, Reynolds J, Quach H, et al. Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21. Br J Haematol. 2024. PMID: 38850184. doi:10.1111/bjh.19578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。